EUVIMED · CrossrefZeitschrift
ESMO Gastrointestinal Oncology
ISSN 2949-8198 · Elsevier BV
Neueste Artikel
Comprehensive characterisation of patients with colorectal cancer and permanently liver-limited disease
Differences in treatment and outcomes between young and older patients with colorectal cancer liver metastases: an AmCORE-based study
Reprogramming the tumor microenvironment in MSS CRC: the role of TKIs in combination with immunotherapy
A single-arm, phase II study of ivonescimab in combination with FOLFOX in advanced HER2 negative gastroesophageal adenocarcinomas
Transarterial chemoembolization combined with immunotherapy-based treatments versus TACE alone in unresectable hepatocellular carcinoma: a systematic review and network meta-analysis
Real-world outcomes and prognostic factors of trifluridine/tipiracil plus bevacizumab in metastatic colorectal cancer: a multicenter study in Spain
Checkpoint inhibitors in microsatellite instability-high metastatic colorectal cancer: treatment strategies, specificities, and care management questions
Regorafenib use in patients with unresectable hepatocellular carcinoma: analyses of subgroups of special interest in the observational REFINE study
DESTINY-Gastric05 phase III trial of first-line trastuzumab deruxtecan, chemotherapy, and pembrolizumab in HER2-positive gastric or gastroesophageal junction cancer
Readministration of nivolumab for patients with advanced gastric cancer: a case series
Distinct clinicopathological and survival profiles of CLDN18.2 and PD-L1 expression in advanced gastric cancer and gastroesophageal junction adenocarcinoma
Real-world treatment patterns and outcomes in biliary tract cancer: a Danish retrospective cohort study
Temporal dynamics of CLDN18.2 expression following zolbetuximab treatment in advanced gastric cancer
Continuum of care and survival in patients with metastatic colorectal cancer: results of the real-world prospective, longitudinal cohort PROMETCO study
Characterization of tumor-associated microbiome in multifocal small intestinal neuroendocrine tumors (SI-NETs)
The clinical utility of an mGPS and SII combined score in patients with advanced gastric cancer treated with nivolumab monotherapy
Breath- and blood-based molecular assessment for gastroesophageal cancer
Feasibility of stereotactic radiotherapy with pembrolizumab in patients with deficient mismatch repair/microsatellite unstable metastatic colorectal cancer
Consistency of a clinical decision support system with molecular tumour board recommendations for tumour sequencing-guided treatment of pancreatic cancer
Safety and efficacy of first-line nivolumab plus chemotherapy for HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma: real-world data analysis
Current practices and challenges in implementing precision medicine for upper gastrointestinal cancers in European academic centers: an EORTC survey
High prevalence of NTRK fusions in sporadic dMMR/MSI mCRC RAS/RAF wild-type: an opportunity for a post-immune checkpoint inhibitors progression rescue strategy
Concordance of PD-L1 status in primary gastroesophageal adenocarcinoma and matched peritoneal metastases: a single institution study
PRABITAS study design: a pragmatic, randomized phase III trial of bi-weekly versus conventional trifluridine/tipiracil plus bevacizumab for metastatic colorectal cancer
Oligometastatic disease in esophagogastric cancer: an update of recommendations on definition, diagnosis, and treatment
Phase III trial of short-course radiotherapy followed by CAPOXIRI versus CAPOX in locally advanced rectal cancer: the ENSEMBLE trial
ASCEND: a randomised, double-blinded, placebo-controlled, phase II study of gemcitabine and nab-paclitaxel with LSTA1 in untreated metastatic pancreatic adenocarcinoma. An Australasian Gastro-Intestinal Trials Group (AGITG) trial
Neoadjuvant immunotherapy for early-stage hepatocellular carcinoma: the arts and science
Individualizing multi-modality therapy for locally advanced rectal cancer: incorporating new data into practice
Immune checkpoint inhibition (ICI) in current systemic therapies for hepatocellular carcinoma (HCC)
EUVIMED